Kestra Medical Technologies (NASDAQ:KMTS) Insider Brian Daniel Webster Sells 15,000 Shares

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $20.81, for a total transaction of $312,150.00. Following the sale, the insider owned 395,467 shares in the company, valued at approximately $8,229,668.27. This trade represents a 3.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Brian Daniel Webster also recently made the following trade(s):

• On Friday, May 15th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $20.96, for a total transaction of $314,400.00.
• On Wednesday, April 15th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $20.04, for a total transaction of $300,600.00.

Kestra Medical Technologies Price Performance

NASDAQ KMTS traded down $0.15 during trading on Wednesday, reaching $19.08. 280,256 shares of the company traded hands, compared to its average volume of 316,939. Kestra Medical Technologies, Ltd. has a 1-year low of $13.25 and a 1-year high of $30.00. The company has a market cap of $1.11 billion, a price-to-earnings ratio of -4.82 and a beta of 0.83. The stock’s 50 day moving average price is $20.70 and its two-hundred day moving average price is $22.97. The company has a debt-to-equity ratio of 0.15, a quick ratio of 7.32 and a current ratio of 7.32.

Kestra Medical Technologies (NASDAQ:KMTS) last posted its earnings results on Tuesday, March 17th. The company reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.01). Kestra Medical Technologies had a negative return on equity of 65.49% and a negative net margin of 171.87%.The company had revenue of $24.55 million for the quarter. The firm’s quarterly revenue was up 62.7% on a year-over-year basis. As a group, analysts anticipate that Kestra Medical Technologies, Ltd. will post -2.34 EPS for the current year.

Institutional Trading of Kestra Medical Technologies

Large investors have recently made changes to their positions in the business. California State Teachers Retirement System increased its stake in shares of Kestra Medical Technologies by 39.2% in the first quarter. California State Teachers Retirement System now owns 27,835 shares of the company’s stock valued at $555,000 after buying an additional 7,844 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in Kestra Medical Technologies by 6.6% during the 1st quarter. The Manufacturers Life Insurance Company now owns 92,515 shares of the company’s stock worth $1,844,000 after buying an additional 5,731 shares in the last quarter. Quantinno Capital Management LP acquired a new position in Kestra Medical Technologies during the 1st quarter worth about $431,000. Sei Investments Co. grew its holdings in Kestra Medical Technologies by 22.6% during the 1st quarter. Sei Investments Co. now owns 237,116 shares of the company’s stock worth $4,726,000 after acquiring an additional 43,753 shares during the last quarter. Finally, Spartan Wealth Advisory Services LLC acquired a new stake in Kestra Medical Technologies in the 1st quarter valued at about $603,000.

Wall Street Analysts Forecast Growth

KMTS has been the topic of several recent analyst reports. The Goldman Sachs Group reduced their target price on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a research note on Thursday, April 9th. BTIG Research restated a “buy” rating and issued a $32.00 price target on shares of Kestra Medical Technologies in a research report on Tuesday, April 7th. Finally, Weiss Ratings cut shares of Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $27.40.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.